Seminar

Update on recent initiatives of the European Commission on SPC

Update on recent initiatives of the European Commission on SPC

Update on recent initiatives of the European Commission on SPC

22.03.2016

In October 2015, the European Commission issued “A Single Market Strategy for Europe” COM(2015) 550 final. One of goals of this strategy is to consolidate Europe’s IP framework. For the pharmaceutical industry, the question arises as to how the upcoming unitary patent will work together with the national SPCs.

The Commission indicated that it will consider initiatives:

  • To address uncertainties about how the unitary patent will work together with current EU rules on SPCs;
  • In relation to the scope of the ‘Bolar’ and research exemptions in view of the upcoming establishment of the Unified Patent Court;
  • To introduce targeted SPC manufacturing waiver for export purposes.

That is why our Brussels life sciences experts are organising a seminar dedicated to these important topics. The seminar aims to present to present the current legal landscape and legal implications of the foreseen developments at both European and international levels to professionals of the pharmaceutical industry.

Below you will find an outline of the main topics that are discussed during the seminar.

 

Team

Related news

14.10.2021 NL law
NFTs: New legal challenges on the horizon

Short Reads - Non-Fungible Tokens, widely known as NFTs, have recently gained much attention due to their role in the transfer of digital artworks. The market for NFTs grew from USD 13.5m in the first six months of 2020 to USD 2.5bn in the first half of 2021 and is still growing at an expansive rate. Notwithstanding their increasing popularity in the world of art, NFTs have many potential applications. In this blog Maciek Bednarski, Annemijn Witkam and Roderik Vrolijk explain what NFTs are and describe some of the legal challenges they will bring about.

Read more